Allogeneic stem cell therapy - Stematix

Drug Profile

Allogeneic stem cell therapy - Stematix

Alternative Names: Allostrome

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stematix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cartilage disorders; Joint disorders; Myocardial infarction

Most Recent Events

  • 23 Jan 2018 No development reported - Phase-II for Cartilage disorders in USA (Parenteral)
  • 23 Jan 2018 No development reported - Phase-II for Joint disorders in USA (Parenteral)
  • 23 Jan 2018 No development reported - Phase-III for Myocardial infarction in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top